synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Nevertheless, alpha-synuclein aggregates to form insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. These disorders are known as synucleinopathies. In vitro models of synucleinopathies revealed that aggregation of alpha-synuclein may lead to various cellular disorders including microtubule impairment, synaptic and mitochondrial dysfunctions, oxidative stress as well as dysregulation of Calcium signaling, proteasomal and lysosomal pathway. Alpha-synuclein is the primary structural component of Lewy body fibrils. Occasionally, Lewy bodies contain tau protein; however, alpha-synuclein and tau constitute two distinctive subsets of filaments in the same inclusion bodies. Alpha-synuclein pathology is also found in both sporadic and familial cases with Alzheimer's disease. The alpha-synuclein seed amplification assay (SAA) using cerebrospinal fluid demonstrated high diagnostic performance in distinguishing synucleinopathies with Lewy bodies from control subjects. Additionally, SAA kinetics are associated with cognitive impairment and predict the development of dementia. The aggregation mechanism of alpha-synuclein is uncertain. There is evidence of a structured intermediate rich in beta structure that can be the precursor of aggregation and, ultimately, Lewy bodies. A single molecule study in 2008 suggests alpha-synuclein exists as a mix of unstructured, alpha-helix, and beta-sheet-rich conformers in equilibrium.
== Production == Plans to create a Nick Fury live action production were circulated as early as September 1986, but it was not until mid-May 1995 that Fox Broadcasting announced the acquisition from New World Entertainment of a Nick Fury series pilot, to be broadcast in 1996. The film was originally sold to Paramount Pictures, with Debra Hill and Lynda Obst as producers, Greg Pruss to write and Stephen Herek originally attached to direct. The teleplay was written by David S. Goyer several years before the film was made, and Goyer was not otherwise involved as he was working on the television series Sleepwalkers. Despite some misgivings within the studio, the producers cast David Hasselhoff in the lead role "to give SHIELD some recognizable star power". The production also markedly "respected and utilized the comic roots of the project", incorporating "a who's who of the Marvel spy scene" and retaining details such as Fury's eyepatch. Goyer was not enthusiastic about the casting of David Hasselhoff, but in hindsight said, "Hasselhoff turned out to be the best thing in it. He got the joke. The script was meant to be very tongue in cheek, and Hasselhoff understood that. Goyer described the film overall as "pretty mediocre". Hasselhoff was reportedly signed for five additional Nick Fury television films, which did not materialize. Shooting for the project occurred between May and June 1997 in Vancouver, British Columbia, Canada.
=== Breastfeeding === Progestogen-only contraceptives such as an IUD are not believed to affect milk supply or infant growth. However, a study in the Mirena application for FDA approval found a lower continuation of breastfeeding at 75 days in hormonal IUD users (44%) versus copper IUD users (79%). When using Mirena, about 0.1% of the maternal dose of levonorgestrel can be transferred via milk to the nursed infant. A six-year study of breastfed infants whose mothers used a levonorgestrel-only method of birth control found the infants had increased risk of respiratory infections and eye infections, though a lower risk of neurological conditions, compared to infants whose mothers used a copper IUD. No longer-term studies have been performed to assess the long-term effects on infants of levonorgestrel in breast milk. There are conflicting recommendations about use of Mirena while breastfeeding. The U.S. CDC does not recommend any hormonal method as a first choice of contraceptive for nursing mothers, although progestin-only methods, such as Mirena, may be used with close follow-up or when the benefits outweigh the risks. The World Health Organization recommends against immediate postpartum insertion, citing increased expulsion rates. It also reports concerns about potential effects on the infant's liver and brain development in the first six weeks postpartum. However, it recommends offering Mirena as a contraceptive option beginning at six weeks postpartum even to nursing women.
=== Vanuatu === The Absinthe (Prohibition) Act 1915, passed in the New Hebrides, has never been repealed, is included in the 2006 Vanuatu consolidated legislation, and contains the following all-encompassing restriction: "The manufacture, importation, circulation and sale wholesale or by retail of absinthe or similar liquors in Vanuatu shall be prohibited."
Sources: en.wikipedia.org
== Associated cancers == Numerous in vivo and in vitro studies have demonstrated that PhIP is a potent mutagen and can induce tumors of multiple sites in animal models. PhIP was positive in bacterial (Ames) test and induced chromosomal abnormalities in human and Chinese hamster cells in vitro. PhIP has also formed DNA adducts in vivo in both rats and monkeys. PhIP has been tested for carcinogenicity in both mice and rats by oral administration. Increases in lymphomas were seen in mice and increases in adenocarcinomas of the small and large intestine in males and mammary adenocarcinomas in female were seen in rats. Also, an increasing number of epidemiological studies have evaluated the association of well-done meat intake and HCA exposure with cancer risk in humans. In general, these studies have reported that high intake of well-done and/or high exposure to PhIP may be associated with cancer of the colorectum, breast, prostate, pancreas, lung, stomach, and esophagus. PhIP has been shown to induce DNA adducts and mutations. These adducts have been found in a wide variety of sensitive tissues and organs such as the colon. However, adducts also formed in sites that did not commonly form tumors, such as the kidneys. In humans receiving a dose of PhIP equivalent to that found in very well-done chicken, DNA and protein adducts were formed in the colon and blood. However, the adducts were unstable and declined over a 24-hour period.
Arias was elected president in 1968 following a populist campaign. Soon after taking office he launched a purge of the National Guard, sending much of its general staff into "diplomatic exile" or retirement. In response, Torrijos and a few other officers led a coup against him, ousting him after an eleven-day presidency. The coup was set in motion by Martínez, as the leader of the garrison at Chiriquí, and received the support of most military officers. A power struggle followed between the various forces involved in the coup, and chiefly between Torrijos and Martínez. Noriega was an important supporter of Torrijos during this conflict. In February 1969, Torrijos's men seized Martínez and exiled him to Miami giving Torrijos control of the country. At the end of 1969, Torrijos went to Mexico on holiday. A coup was launched in his absence, in which Noriega's loyalty allowed Torrijos to hang on to power, greatly enhancing Torrijos's image. Noriega was promoted to captain a month after the coup attempt: just 18 months later, in August 1970, Torrijos promoted him to the position of lieutenant colonel and appointed him chief of military intelligence. According to Dinges, by this point Noriega had left his undisciplined past behind him. When Arias's supporters launched a guerrilla uprising in his home province, Noriega as the head of intelligence played an important role in putting it down within a year. Torrijos retained power as a military ruler until 1981: during this time he negotiated the Torrijos–Carter Treaties with U.S.
The Rigveda is one of the four oldest and most sacred collections of stories in Hinduism. In the Rigveda soma is a drink consumed by two of the main gods; Agni and Indra. In the texts, the drink helped the gods in battle by strengthening them physically. Because of this, soma was given and consumed by warriors before wartime or a battle. The drink was supposed to give the warriors strength and luck in the upcoming conflict. Immortality is also a quality associated with soma due to it being a drink of the divine. At religious ceremonies the drink was consumed to give consumers longevity in life. At birth the drink was also given to the babies for these same reasons. In Zoroastrianism, the drink is called haoma and has similar uses. Just like in Hinduism, the drink was related to immortality and long life. Haoma was the first thing newborns drank. This assured the child would be healthy and live a long life. The drink was also administered to people close to death to revive them back into good health. The physical appearance of Ephedra is also a reason it is believed to be the soma plant. According to the Vedic text Rigveda, the plant comprising soma is shaped like an arrow. Ephedra sinica is a gymnosperm that forms stalks with buds on the end. It is easy to see how this shape could be described as an arrow. Another text refers to soma as a twig, which is much like Ephedra sinica when it is dried out.
PSSM is most prevalent in American Quarter Horses and their related breeds (Paint horse, Appaloosa, Appendix Quarter Horse), Draft horse breeds (especially Belgian Draft and Percherons), and Warmblood breeds. The Belgian Draft been shown to have a 36% prevalence of PSSM. Other breeds that have been diagnosed with PSSM include the Arabian, Lipizzaner, Morgan, Mustang, Peruvian Paso, Rocky Mountain Horse, Standardbred, Tennessee Walking Horse, Thoroughbred, and National Show Horse. It has been suggested that the GSY1 mutation provided some benefit to hard working animals with poor-quality diets, and is now damaging members of those "thrifty" breeds that are managed with moderate to low levels of work and diets high in non-structural carbohydrates. PSSM Type 1 (homozygous or heterozygous for the GSY1 mutation) is more common in Quarter Horses and their related breeds, and draft breeds, while PSSM Type 2 (negative for the GSY1 mutation) is more commonly seen in other breeds, including warmbloods. There is no sex predilection to the disease.
1993/1947) Learning for Work (Miscellaneous Provisions) Order 1993 (S.I. 1993/1949) Act of Adjournal (Consolidation Amendment) (Courses for Drink-drive Offenders) 1993 (S.I. 1993/1955) Act of Sederunt (Sheriff Court Ordinary Cause Rules) 1993 (S.I. 1993/1956) Double Taxation Relief (Taxes on Income) (General) (Manufactured Overseas Dividends) Regulations 1993 (S.I. 1993/1957) Dartford–Thurrock Crossing (Amendment) Regulations 1993 (S.I. 1993/1961) Harwich Haven Harbour Revision Order 1993 (S.I. 1993/1962) A4 Trunk Road (Great West Road, Hounslow) (Prescribed Routes) Order 1993 (S.I. 1993/1963) London South Circular Trunk Road (A205) (Westhorne Avenue, Lewisham) (Prohibition of Use of Gaps in Central Reserve) Order 1993 (S.I. 1993/1964) Civil Aviation (Route Charges for Navigation Services) Regulations 1993 (S.I. 1993/1965) Importation of Bovine Semen (Amendment) Regulations 1993 (S.I. 1993/1966) Animals and Animal Products (Import and Export) (Amendment) Regulations 1993 (S.I. 1993/1967) Criminal Justice Act 1993 (Commencement No. 1) Order 1993 (S.I. 1993/1968) Education (Teachers) (Amendment) Regulations 1993 (S.I. 1993/1969) Clyde Port Authority (Dissolution) Order 1993 (S.I. 1993/1970) Education Act 1993 (Commencement No. 1 and Transitional Provisions) Order 1993 (S.I. 1993/1975) Education (London Oratory School) (Exemption from Pay and Conditions Orders) Order 1993 (S.I. 1993/1976) Further Education (Attribution of Surpluses and Deficits) (The Ridge College) Regulations 1993 (S.I.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.